Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Toripalimab Plus Radiotherapy After Radical Cystectomy in High-Risk Muscle-Invasive Bladder Cancer
ChiCTR2500106158Phase 2Not yet recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in bladder cancer, sponsored by Chongqing University Cancer Hospital. Primary endpoint: 2-year disease-free survival. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
bladder cancer
Beyond the preview
Go deeper on ChiCTR2500106158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106158.